Stay Updated

Melanotan 1

Also known as: Melanotan I, Afamelanotide, MT-I, MT-1, [Nle4-D-Phe7]-α-MSH, NDP-α-MSH, Scenesse

3 notable studies · 4 references

View Supplier Listings Take This Melanotan 1 Study With You

TLDR

Afamelanotide, historically known as Melanotan I, is a synthetic α-MSH analogue and MC1R agonist with extensive human evidence for increasing pigmentation and photoprotection and FDA approval as Scenesse to increase pain-free light exposure in adults with erythropoietic protoporphyria.

Research Supports

  • Studied for its established role in increasing light tolerance in erythropoietic protoporphyria (EPP)
  • Investigated for effects on skin pigmentation and melanogenesis via MC1R
  • Studied for photoprotection in photosensitivity conditions such as solar urticaria
  • Investigated alongside NB-UV-B phototherapy for vitiligo
  • Studied for long-term real-world outcomes in EPP patients after approval

Observations Reported in Research

  • Pivotal EPP trials: afamelanotide significantly increased pain-free light exposure vs placebo (Langendonk et al., 2015)
  • U.S. trial median pain-free direct-light exposure at six months was 69.4 hours vs 40.8 hours with placebo
  • Increased pigmentation and reduced measures of UV-associated skin damage in 65 fair-skinned volunteers (Barnetson et al., 2006)
  • Combination with NB-UV-B produced faster, greater repigmentation in some vitiligo patients (Lim et al., 2015)
  • Increased melanin density and light tolerance reported in a small solar urticaria study

These are brief summaries of what the referenced research examined or reported — not conclusions about safety or effectiveness, and not medical advice. See Notable Studies and Sources & References below for the full context and citations.

At a Glance

Classification: Synthetic α-melanocyte-stimulating hormone analogue; melanocortin-1 receptor agonist; melanocortin peptide

Afamelanotide is a synthetic analogue of the endogenous peptide hormone α-melanocyte-stimulating hormone (α-MSH). It was originally known during development as Melanotan I. Unlike Melanotan II, afamelanotide ultimately became an approved medicine: Scenesse (afamelanotide) was FDA-approved in 2019 to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria (EPP). Access Data FDA Its principal target is: MC1R — melanocortin-1 receptor ↓ melanocyte signaling ↓ increased eumelanin production ↓ increased pigmentation and photoprotection. That makes afamelanotide an unusually useful Aminodex profile: Melanotan I and afamelanotide refer to the same underlying peptide analogue—but a research-market “MT-I” product should not automatically be treated as equivalent to the regulated Scenesse drug product.

What Is Melanotan 1?

Natural α-MSH is a 13-amino-acid melanocortin peptide. Afamelanotide is also 13 amino acids long but contains two important substitutions: • Norleucine at position 4 • D-phenylalanine at position 7 These modifications increase stability and melanocortin activity relative to endogenous α-MSH. A 2026 pharmaceutical-analysis paper continues to identify afamelanotide explicitly as Melanotan-1 and [Nle4-D-Phe7]-α-MSH. PubMed The result is a potent melanocortin agonist with particularly important activity at MC1R.

What Are Researchers Studying?

Erythropoietic protoporphyria

This is afamelanotide's established therapeutic use. EPP is a rare disorder in which accumulation of protoporphyrin IX produces extreme sensitivity to visible light. Exposure can produce severe burning pain despite little obvious skin damage. Afamelanotide increases melanin production, providing additional photoprotection. In two randomized controlled trials, patients receiving afamelanotide experienced significantly greater pain-free light exposure than placebo recipients. Quality-of-life measures also improved. PubMed This evidence ultimately supported regulatory approval.

Melanogenesis and pigmentation

Afamelanotide activates MC1R on melanocytes. That promotes signaling favoring production of eumelanin, the darker melanin pigment with photoprotective properties. Human experimental research clearly demonstrates increased skin pigmentation. In a study of 65 fair-skinned volunteers, [Nle4-D-Phe7]-α-MSH significantly increased pigmentation and reduced several measures of UV-associated skin damage. PubMed So unlike MT-II tanning claims, the pigmentation effect here has substantial controlled human evidence.

Photoprotection

Melanin absorbs and disperses ultraviolet and visible radiation and can reduce photochemical injury. Afamelanotide therefore provides an unusual form of systemic photoprotection. This has been investigated not only in EPP but in other photosensitivity conditions. A small study in solar urticaria found increased melanin density and increased tolerance to experimentally administered wavelengths of light following afamelanotide treatment. PubMed However: Photoprotection does not mean immunity from UV damage or skin cancer.

Vitiligo

Afamelanotide has also been investigated alongside narrow-band UV-B phototherapy for vitiligo. A randomized multicenter trial involving 55 adults compared NB-UV-B alone with NB-UV-B plus afamelanotide. Combination treatment produced faster and greater repigmentation in some patient groups. PubMed This remains distinct from its FDA-approved EPP indication.

Long-term EPP outcomes

Real-world evidence has continued accumulating after approval. A 2026 Austrian study reported improvements in quality of life and light tolerance among patients with EPP receiving afamelanotide. PubMed That's useful for Aminodex because the evidence story doesn't end with the registration trials.

How Does It Work?

The simplified pathway is: Afamelanotide ↓ MC1R ↓ Gs-protein signaling ↓ adenylyl cyclase ↓ increased cAMP ↓ melanogenic transcriptional signaling ↓ increased eumelanin synthesis ↓ greater pigmentation / photoprotection. MC1R signaling also intersects with: • oxidative-stress responses • DNA-damage responses • inflammatory signaling. But its established clinical effect in EPP is centered on increased melanization and improved tolerance of light exposure.

What Does the Research Show?

Human research

Strong. This is not a preclinical research-market compound. Human evidence includes: • controlled pigmentation studies • photoprotection studies • randomized EPP trials • vitiligo trials • long-term observational EPP data • post-approval clinical experience. In the pivotal EPP trials, 74 European and 94 U.S. patients were randomized to afamelanotide or placebo implants. Pain-free direct-light exposure increased significantly with afamelanotide in both studies, and quality of life improved. PubMed

Animal research

Animal studies contributed substantially to early melanocortin pharmacology and afamelanotide development. But this profile no longer needs animal efficacy studies to support its primary indication because controlled human evidence exists.

In-vitro research

Cellular research has extensively characterized: • MC1R activation • cAMP signaling • melanogenesis • melanocyte biology • α-MSH analogues • pigment production. Modern pharmaceutical work also continues to characterize the molecule's stability and degradation products. PubMed

Notable Studies

Afamelanotide for Erythropoietic Protoporphyria

human

Langendonk JG, Balwani M, Anderson KE, et al. · 2015

Two trials enrolled 168 patients with EPP across the U.S. and Europe. Afamelanotide significantly increased pain-free exposure to sunlight compared with placebo and improved quality-of-life measures. In the U.S. trial, median pain-free direct-light exposure at six months was 69.4 hours versus 40.8 hours with placebo. PubMed

Limitations: EPP is rare, resulting in relatively small trial populations. The unusual behavioral adaptation of EPP patients—actively avoiding sunlight—also makes conventional photoprotection endpoints difficult to measure.

View publication →

[Nle4-D-Phe7]-α-Melanocyte-Stimulating Hormone Significantly Increased Pigmentation and Decreased UV Damage in Fair-Skinned Caucasian Volunteers

human

Barnetson RStC, Ooi TKT, Zhuang L, et al. · 2006

Sixty-five participants completed treatment with the synthetic melanotropin. Afamelanotide increased epidermal pigmentation and reduced measures of UV-associated skin injury, providing direct human evidence for the peptide's melanogenic and photoprotective effects. PubMed

Limitations: This was experimental photoprotection research rather than evidence that afamelanotide prevents skin cancer or eliminates the need for conventional sun protection.

View publication →

Afamelanotide and Narrowband UV-B Phototherapy for the Treatment of Vitiligo: A Randomized Multicenter Trial

human

Lim HW, Grimes PE, Agbai O, et al. · 2015

Fifty-five adults with nonsegmental vitiligo received NB-UV-B phototherapy with or without afamelanotide implants. Combination therapy accelerated and enhanced repigmentation in selected populations. PubMed

Limitations: Small study; afamelanotide was added to established phototherapy, making this different from afamelanotide monotherapy. Vitiligo is not its FDA-approved U.S. indication.

View publication →

What We Still Don't Know

Despite strong evidence for EPP, questions remain about: • Benefits in other photodermatoses • Long-term outcomes beyond established EPP use • Role in vitiligo • Whether increased pigmentation meaningfully reduces long-term skin-cancer risk • Effects across different MC1R genotypes • Long-term effects of repeated pharmacologic melanocortin stimulation • Potential applications outside photoprotection. These uncertainties shouldn't obscure what is established: afamelanotide has demonstrated human clinical efficacy for EPP and is an FDA-approved drug for that indication. Access Data FDA

Take the Melanotan 1 research with you.

Get the Aminodex Melanotan 1 Brief—a concise summary of the research, notable studies, evidence types, limitations, and references.

One-time email. We do not add you to any mailing list.

Sources & References

  1. Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for Erythropoietic Protoporphyria. New England Journal of Medicine. 2015.
  2. Barnetson RStC, Ooi TKT, Zhuang L, et al. [Nle4-D-Phe7]-α-Melanocyte-Stimulating Hormone Significantly Increased Pigmentation and Decreased UV Damage in Fair-Skinned Caucasian Volunteers. Journal of Investigative Dermatology. 2006.
  3. Lim HW, Grimes PE, Agbai O, et al. Afamelanotide and Narrowband UV-B Phototherapy for the Treatment of Vitiligo. JAMA Dermatology. 2015.
  4. FDA. Scenesse (afamelanotide) orphan designation and marketing approval.

Supplier Listings

A directory of relevant research suppliers for this compound is not yet available.